Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries (Q38150706)

29 August 2017

title

Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries (English)

1 reference

29 August 2017

0 references

1 reference

Brian Godman

2

0 references

author name string

Ulrik Hesse

1

1 reference

29 August 2017

Max Petzold

3

1 reference

29 August 2017

Andrew Martin

4

1 reference

29 August 2017

Rickard E Malmström

5

1 reference

29 August 2017

publication date

1 December 2013

1 reference

Applied Health Economics and Health Policy

29 August 2017

published in

1 reference

29 August 2017

volume

11

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

677-685

1 reference

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Potential savings without compromising the quality of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Optimising management of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Patient socioeconomic determinants for the choice of the cheapest molecule within a cluster: evidence from Belgian prescription data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

21 January 2018

Using clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

Association of Treatment With Losartan vs Candesartan and Mortality Among Patients With Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40258-013-0059-4

10.1007/S40258-013-0059-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1036593051

0 references

1 reference